Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Bicycle Therapeutics plc. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bicycle Therapeutics plc (“Bicycle” or “the Company”) (NASDAQ: BCYC). Investors who purchased Bicycle securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Bicycle has violated federal securities laws.
Bicycle Investigation Details
On October 31, 2025, RBC Capital Markets analyst Leonid Timashev downgraded Bicycle to Sector Perform from Outperform, citing delays in development of zelenectide pevedotin, which is in phase 2/3 development for metastatic urothelial cancer, due to pushing dose selection to the first quarter of 2026. Timashev noted that the urothelial cancer treatment space is becoming increasingly competitive and asserted that any further delays from Bicycle will only help sales of a competing Pfizer product. Following the downgrade, Bicycle’s American Depositary Receipt (“ADR”) price fell $0.69 per ADR, or 7.88%, to close at $8.07 per ADR on October 31, 2025.
What’s Next for Bicycle Investors?
If you are aware of any facts relating to this investigation or purchased Bicycle securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
BCYC — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”